Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein...
15 insider purchases on record · latest filing 2026-06-22.
Insiders have also filed 1 sale transaction at KTTA.